polaris semaglutide Group Acquires Genovior Biotech Semaglutide | GLP-1R Agonist |

obesity pharmacotherapy Medical Research Interests Public Health Interests ORCID 0000-0003-1446-0991 Y-Weight: Yale Obesity Research Center Investigating novel pharmacological therapeutics for obesity treatment and probing the mechanisms of obesity in translational physiology studies View Lab Website Research at a Glance Yale Co-Authors Publications Timeline Research Interests Yuan Lu, ScD Harlan Krumholz, MD, SM Rajita Sinha, PhD Michelle Van Name, MD Wendy Silverman, PhD, ABPP Alissa Chen, MD, MPH, MHS Publications 2026 Survodutide Once Weekly for the Treatment of Adults with Obesity le Roux C, Wharton S, Startseva E, Kloer I, Hussain S, Unseld A, Bozkurt B, Ard J, Bays H, Bogdaski P, Ekinci E, Jastreboff A , Ji L, Ogawa W, Pedersen S, Pietilinen K, Sattar N, Seufert J, Stenlf K, van Beek A, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan L

Efficacy and safety of onceweekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56week, openlabel, randomized clinical trial

It is often used in topical products because it may support skin repair, collagen activity, and overall skin quality

Means by which growth arrest can be overcome and how melanocytic nevi relate to melanoma are also considered

Foundayo is emerging as a leader with its flexibilityits an oral GLP-1 option with no food or water restrictions